Urinary epidermal growth factor/monocyte chemotactic peptide 1 ratio as non-invasive predictor of Mayo clinic imaging classes in autosomal dominant polycystic kidney disease

[1]  R. Gansevoort,et al.  Use of the Urine-to-Plasma Urea Ratio to Predict ADPKD Progression. , 2021, Clinical journal of the American Society of Nephrology : CJASN.

[2]  D. Peters,et al.  Salsalate, but not metformin or canagliflozin, slows kidney cyst growth in an adult-onset mouse model of polycystic kidney disease , 2019, EBioMedicine.

[3]  E. Jatem,et al.  Association between urinary biomarkers and disease progression in adults with autosomal dominant polycystic kidney disease , 2019, Clinical kidney journal.

[4]  D. Trouet,et al.  Epidermal growth factor and its influencing variables in healthy children and adults , 2019, PloS one.

[5]  L. Cantley,et al.  Mcp1 Promotes Macrophage-Dependent Cyst Expansion in Autosomal Dominant Polycystic Kidney Disease. , 2018, Journal of the American Society of Nephrology : JASN.

[6]  U. Udomsubpayakul,et al.  Urine epidermal growth factor, monocyte chemoattractant protein‐1 or their ratio as predictors of complete remission in primary glomerulonephritis , 2018, Cytokine.

[7]  M. García-González,et al.  The Genetic and Cellular Basis of Autosomal Dominant Polycystic Kidney Disease—A Primer for Clinicians , 2017, Front. Pediatr..

[8]  J. Burgerhof,et al.  Urinary Biomarkers to Identify Autosomal Dominant Polycystic Kidney Disease Patients With a High Likelihood of Disease Progression , 2017, Kidney international reports.

[9]  Vicente E. Torres,et al.  Total Kidney Volume Is a Prognostic Biomarker of Renal Function Decline and Progression to End-Stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease , 2017, Kidney international reports.

[10]  A. Nongnuch,et al.  Urine Epidermal Growth Factor, Monocyte Chemoattractant Protein-1 or Their Ratio as Biomarkers for Interstitial Fibrosis and Tubular Atrophy in Primary Glomerulonephritis , 2016, Kidney and Blood Pressure Research.

[11]  A. Tong,et al.  Recent advances in autosomal‐dominant polycystic kidney disease , 2016, Internal medicine journal.

[12]  R. Gansevoort,et al.  Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[13]  C. Férec,et al.  The PROPKD Score: A New Algorithm to Predict Renal Survival in Autosomal Dominant Polycystic Kidney Disease. , 2016, Journal of the American Society of Nephrology : JASN.

[14]  K. Shedden,et al.  Tissue transcriptome-driven identification of epidermal growth factor as a chronic kidney disease biomarker , 2015, Science Translational Medicine.

[15]  R. Gansevoort,et al.  Urinary EGF Receptor Ligand Excretion in Patients with Autosomal Dominant Polycystic Kidney Disease and Response to Tolvaptan. , 2015, Clinical journal of the American Society of Nephrology : CJASN.

[16]  Philip McFarlane,et al.  Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease: A Biomarker of Disease Progression and Therapeutic Efficacy. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[17]  Paul Robinson,et al.  A systematic review of the predictors of disease progression in patients with autosomal dominant polycystic kidney disease , 2015, BMC Nephrology.

[18]  M. Gadjeva,et al.  Macrophage migration inhibitory factor promotes cyst growth in polycystic kidney disease. , 2015, The Journal of clinical investigation.

[19]  N. Perico,et al.  Effects of MCP-1 Inhibition by Bindarit Therapy in a Rat Model of Polycystic Kidney Disease , 2014, Nephron.

[20]  Ajay V. Srivastava,et al.  Autosomal dominant polycystic kidney disease. , 2014, American family physician.

[21]  V. Torres,et al.  Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease. , 2014, The Journal of clinical investigation.

[22]  J. Fox,et al.  Urinary MCP1 and Microalbumin increase prior to onset of Azotemia in mice with polycystic kidney disease. , 2014, Comparative medicine.

[23]  L. Cantley,et al.  Macrophages promote cyst growth in polycystic kidney disease. , 2011, Journal of the American Society of Nephrology : JASN.

[24]  Ning He,et al.  Systems biology of autosomal dominant polycystic kidney disease (ADPKD): computational identification of gene expression pathways and integrated regulatory networks. , 2009, Human molecular genetics.

[25]  G. M. Mulder,et al.  Epidermal growth factor receptor signaling in the kidney: key roles in physiology and disease. , 2008, Hypertension.

[26]  F. Mattace-Raso,et al.  The ratio of epidermal growth factor to monocyte chemotactic peptide-1 in the urine predicts renal prognosis in IgA nephropathy. , 2008, Kidney international.

[27]  D. Wallace,et al.  J Am Soc Nephrol 14: 2588–2595, 2003 Urinary Excretion of Monocyte Chemoattractant Protein-1 in Autosomal Dominant Polycystic Kidney Disease , 2022 .

[28]  S. Milani,et al.  Expression of epidermal growth factor and its receptor in normal and diseased human kidney: an immunohistochemical and in situ hybridization study. , 1996, Kidney international.

[29]  Achim Zeileis,et al.  Partykit: a modular toolkit for recursive partytioning in R , 2015, J. Mach. Learn. Res..

[30]  L. Gesualdo,et al.  Urinary epidermal growth factor concentration in patients affected by ADPKD. , 1995, Contributions to nephrology.

[31]  Y. Tomino,et al.  Growth factor gene expression in kidney of murine polycystic kidney disease. , 1993, Journal of the American Society of Nephrology : JASN.